Compare Delta Air Lines, Inc. (DAL) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Enveric Biosciences Inc — how do they compare? Delta Air Lines, Inc. trades at $85.65 (market cap $56.23B), while Enveric Biosciences Inc trades at $1.28 (market cap $5.32M). The key difference: Delta Air Lines, Inc. is far larger — about 10569.5× Enveric Biosciences Inc's market cap, and Delta Air Lines, Inc. pays a 0.91% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| DAL | ENVB | |
|---|---|---|
Market Cap | $56.23B | $5.32M |
Sector | Industrials | Health |
52-Week High | $93.66 | $17.40 |
52-Week Low | $51.15 | $1.28 |
Enterprise Value | $71.55B | $408.82K |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $86.19, down 1.37% on the day, with a bullish technical outlook supported by strong earnings beats and positive analyst sentiment. The stock shows solid fundamentals with a P/E of 14.29 and net income margin of 5.78%, while recent news highlights premium demand resilience and AI-driven customer satisfaction improvements. Cash flow trends have strengthened, with net cash flow turning positive in 2025 at $1.08 billion.
The outlook remains favorable with an 81.82% analyst buy rating and a $108.27 consensus price target implying 26% upside. Key risks include fuel cost volatility and competitive pressures, but strong institutional support and consistent earnings performance underpin potential for continued growth amid stable travel demand.
ENVB trades at $1.33, down 1.48% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows significant financial challenges with negative ROE of -257.95% and ROA of -218.01%, though it has consistently beaten earnings expectations in recent quarters. Recent news highlights active participation in investor conferences and progress with EB-003 drug candidate development.
While analyst consensus is 75% buy-rated, the stock faces substantial fundamental risks from negative profitability and cash burn. Investment opportunity exists if clinical developments succeed, but shareholders should weigh high operational losses against potential biotech breakthroughs in the neuroplastogenic therapeutics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
